Cancer biotech Inhibrx files for a $75 million IPO
Inhibrx, which is using protein engineering to develop targeted therapies for cancer and rare diseases, filed on Monday with the SEC to raise up to $75 million in an initial public offering.
The La Jolla, CA-based company was founded in 2010 and booked $14 million in revenue for the 12 months ended March 31, 2019. It plans to list on the Nasdaq under the symbol INBX. Inhibrx filed confidentially on January 7, 2019. Evercore ISI, Barclays and Nomura Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
The article Cancer biotech Inhibrx files for a $75 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Latest IPOs Videos
- Nasdaq Kicks Off October With Over 2 Dozen IPOs as Activity Remains Robust Ahead of Election
- Mobile network software provider Mavenir lowers deal size by 8% ahead of $275 million IPO
- Nasdaq’s IPO Momentum Continues to Build, Welcoming 15 Companies This Week
- US IPO Week Ahead: Chinese fintech, pool supplies, and auto insurance lead a diverse 15 IPO week